Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testingPotential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patients.
Pfizer Inc and Western Oncolytics announced that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel technology platform to Pfizer’s cancer vaccine efforts and provides an additional tool to bolster its immuno-oncology portfolio.
Under the terms of the agreement, Pfizer and Western Oncolytics will collaborate on preclinical and clinical development of WO-12 through Phase I trials. Following completion of Phase I trials, Pfizer has an exclusive option to acquire WO-12. Financial terms of the agreement were not disclosed.
“Our goal is to combine WO-12 with our portfolio of promising investigational immunotherapies to explore how these novel combinations could help further enhance the body’s immune response in fighting cancer cells,” said James Merson, Ph.D., Chief Scientific Officer, Vaccine Immunotherapeutics at Pfizer. “We believe that the real advances in immuno-oncology will come from novel combinations, and cancer fighting viruses and vaccines could play a key role in helping transform cancer treatment and potentially enable us to treat more patients.”
WO-12 is a preclinical investigational oncolytic virus. As an in vivo vaccine, it has the potential to be delivered directly to the tumor (intratumoral) or intravenously. More specifically, it is a virus engineered to replicate primarily in cancer cells while delivering several therapeutic genes that modulate the immune system to enhance efficacy against a range of cancers. By replicating inside cancer cells, it is designed to both kill the cancer cell and releases tumor antigens that direct the immune system to recognize the antigens and kill additional cancer cells. WO-12 has potential applications across multiple tumor types.
“We believe this collaboration will create a unique opportunity to accelerate and expand the clinical testing of WO-12 as well as to examine potential combinations with other immunotherapies in the Pfizer portfolio,” said Steve Thorne, PhD, Chief Scientific Officer of Western Oncolytics and inventor of WO-12.
Kurt Rote, CEO of Western Oncolytics, added, “We have been very impressed with the expertise and commitment to success from everyone at Pfizer, and are excited to be partnering this promising therapy with a shared vision of improving the way patients are treated.”
About Pfizer Oncology:
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time. For more information, please visit www.pfizer.com.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. For more information, please visit us at www.pfizer.com. In addition, to learn more, follow us on Twitter at @Pfizer (link is external) and @Pfizer_News (link is external), LinkedIn (link is external), YouTube and like us on Facebook at Facebook.com/Pfizer (link is external).
Western Oncolytics Ltd
Western Oncolytics Ltd. develops novel therapies for patients. The Company commercializes treatments that show promise in early laboratory research and demonstrates their value to patients in clinical trials. The Company believes that its lead technology, the novel immuno-oncolytic therapy WO-12, has the potential to extend the lives of, or outright cure, patients across a wide range of cancer types while avoiding the severe side effects common with current cancer therapies.
Contact:
Pfizer Inc. Media
Allyanna Anglim, 212-733-4945
allyanna.anglim@pfizer.com
or
Pfizer Inc. Investors
Ryan Crowe, 212-733-8160
ryan.crowe@pfizer.com
or
Western Oncolytics
Kurt M. Rote
info@westernoncolytics.com
